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Abstract:  Atherosclerotic vascular disease, diabetes mellitus (DM) and dementia are major global health 
problems. Both endogenous and exogenous factors activate genes functioning in biological processes. This 
review article focuses on gene-activation mechanisms that regress atherosclerosis, eliminate DM type 2 
(DM2), and prevent cognitive decline and dementia.  
Gene-activating compounds upregulating functions of liver endoplasmic reticulum (ER) and affecting lipid and 
protein metabolism, increase ER size through membrane synthesis, and produce an antiatherogenic plasma 
lipoprotein profile. Numerous  gene-activators regress atherosclerosis and reduce the occurrence of 
atherosclerotic disease. The  gene-activators increase  glucose disposal rate  and insulin sensitivity and, by 
restoring normal glucose and insulin levels, remove metabolic syndrome and DM2. Patients with DM2 show an 
improvement of plasma lipoprotein profile and glucose tolerance together with increase in liver phospholipid 
(PL) and cytochrome (CYP) P450. The gene-activating compounds induce hepatic protein and PL synthesis, 
and upregulate enzymes including CYPs and glucokinase, nuclear receptors, apolipoproteins and ABC (ATP-
binding cassette) transporters. They induce reparation of ER structures and eliminate consequences of ER 
stress.  Healthy living habits activate mechanisms that maintain high levels of HDL and apolipoprotein AI, 
promote health, and prevent cognitive decline and dementia. Agonists of liver X receptor (LXR) reduce amyloid 
in brain plaques and improve cognitive performance in mouse models of Alzheimer`s disease.  
The gene activation increases the capacity to withstand cellular stress and to repair cellular damage and 
increases life span. Life free of major health problems and in good cognitive health promotes well-being and 
living a long and active life.  
Keywords: Atherosclerosis, CYP, dementia, diabetes, endoplasmic reticulum, gene activation, HDL, LXR. 
INTRODUCTION  
Our survival depends upon the capacity to 
withstand cellular stress and repair molecular damage 
to maintain physiological functions.  Both endogenous 
and exogenous factors influence  the life maintaining 
activities. They influence the functions of genes that act 
as controllers of metabolic processes. Perturbations in 
lipid and protein metabolism are  common in 
atherosclerotic cardiovascular diseases (CVDs) and 
metabolic disorders such as  obesity, metabolic 
syndrome and type 2 diabetes (DM2) which are major 
health problems worldwide. Coronary heart disease 
(CHD) has been recognised  as the most common 
cause of death in the world [1]. About nine out of ten 
patients with diagnosed DM in the U.S. have DM2 the 
prevalence of which has tripled in the last 30 years [2], 
and the prevalence of metabolic syndrome is rapidly 
increasing to epidemic proportions both in developed 
and developing countries [3].  The combination of 
obesity, elevated blood pressure and poor glucose 
tolerance often associates with elevated triglycerides 
and reduced HDL cholesterol (HDL-C) and together 
comprise  the major components of the metabolic 
syndrome [4].  
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Clinical investigations performed in the 1970s 
revealed that drugs inducing protein synthesis and 
increasing liver proteins,  in proportion to this effect 
produce plasma risk factor profile indicating a low 
probability of developing atherosclerotic disease [5, 6]. 
Studies in the 1980 including DM2 patients revealed 
that these gene-activating agents reduce both blood 
glucose and insulin [7, 8]. More recent studies have 
focused interest on gene-activation  mechanisms 
affecting neuronal and cognitive function [9, 10]. A 
prospective study showed that removing modifiable risk 
factors  of DM has a great reducing impact on the 
incidence of dementia, and suggested the elimination 
of  DM as the principal target for  health promotion 
programmes  [11].  This  review focuses on gene-
activation mechanisms in the  regression of 
atherosclerosis, elimination of DM2, and prevention of 
cognitive decline and dementia.  
LIVER ENDOPLASMIC RETICULUM IN LIPID, 
PROTEIN AND GLUCOSE METABOLISM 
The liver endoplasmic reticulum (ER) is the principal 
site for the synthesis and processing of lipids and 
proteins,  and alterations in ER function influence 
plasma  lipoprotein  levels [12, 13]. Investigations 
performed in the 1960s revealed that induction  of 
hepatic protein and lipid synthesis  increases protein 
and phospholipid (PL) concentrations together with 392    Current Molecular Medicine,  2011, Vol. 11, No. 5  P.V. Luoma 
increase of ER membranes [14-16]. Phenobarbital (PB) 
has widely been used as a prototype for the evaluation 
of ER functions in protein, lipid, carbohydrate and 
xenobiotic metabolism. Studies performed in the 1970s 
and 1980s revealed that patients treated with PB-type 
gene-activating drugs show increase in liver protein 
and PL concentrations and P450 activity [5, 17] and 
decrease in hepatic triglycerides [18]. DM2 patients 
often have hepatic fatty degeneration together with 
increased triglyceride and reduced PL concentrations 
[19], and the gene-activating therapy reduces hepatic 
fat content as seen in light microscopy, and electron 
micrographs show reparation  and increase  in 
hepatocyte and  ER membranes [7]. The therapy has 
similar effects also in obese mice with fatty liver [20]. 
The ER has a central role also in carbohydrate 
metabolism [21], and gene- activating compounds 
affect the fate of glucose. PB treatment reduces the 
activity of ER glucose-6-phosphatase [22] which is 
responsible for hepatic glucose production from 
glycogen breakdown or gluconeogenesis, and induces 
glucokinase [23], the major enzyme in the hepatic 
utilization of glucose.  
HDL AND LDL RISK FACTORS AND ANTI-
ATHEROGENIC MECHANISMS  
HDL is known as the antiatherogenic lipoprotein 
acting in the reverse transport of cholesterol, and low 
density lipoprotein, LDL, as the atherogenic lipoprotein 
transporting cholesterol to tissues, including arteries. 
Apo AI and AII are major apolipoproteins of HDL and 
apo B the apolipoprotein of LDL. Two main subclasses, 
HDL2 and HDL3, can be separated in HDL density 
range. HDL2 is a large lipoprotein with high apo AI and 
PL content [24]. Phosphatidylcholine (PC) is the main 
PL (over 70%) of HDL [25], and the PC- and apo AI-
rich HDL2 is known as the lipoprotein responsible for 
the antiatherogenic effect of HDL [26]. High HDL2-C 
level, HDL2-C/HDL3-C and apo AI/AII ratio, and low 
LDL-C level, and LDL-C/ HDL-C and apo B/apo AI ratio 
indicate a low risk of atherosclerotic disease.  
Sophisticated regulatory systems maintain 
cholesterol homeostasis (reviewed in [27-29]).  They 
include cytochrome (CYP) P450-monooxygenases, 
physiological factors in the catabolism of cholesterol to 
oxysterols and bile acids and activation of cholesterol-
lowering mechanisms [30, 31]. Oxysterols are 
endogenous ligands for liver X receptors (LXR and 
LXR), and suppressors of hydroxyl-methylglutaryl 
CoA reductase (HMGCoAR), the rate-limiting enzyme 
in cholesterol synthesis, and their secretion from cells 
represents a form of cholesterol elimination. The LXRs 
mediate the expression of multiple genes in the 
regulation of cholesterol balance in the body, i.e. its 
cellular efflux, transport, excretion and absorption. 
LXRs upregulate ABC transporters including ABCA1, 
ABCG1, ABCG4, ABCG5 and ABCG8 that shuttle 
intracellular cholesterol for the efflux out of cells, and 
several apolipoproteins including apo AI and E. ABCA1 
is a key playmaker in cholesterol efflux, and a major 
determinant of plasma  HDL level [29]. An  increased 
ABCA1 and ABCG1 expression stimulates cellular 
cholesterol  efflux to lipid  poor apo AI and HDL, 
respectively [28].  
LDL particles accumulated in the arterial wall can 
undergo oxidative modification [32]. Oxidized LDL 
contains products of lipid peroxidation including lipid 
hydroperoxides and oxidized phospholipids which are 
key factors in the initiation and progression of 
atherosclerotic lesions [32, 33]. Apart from the key role 
in cholesterol efflux, LXR activation  is important  in 
protecting cells from the atherogenic effects of lipid 
peroxides and inflammation [34]. HDL, apo AI, and apo 
AI-mimetic peptides prevent LDL oxidation  and 
decrease atherosclerotic lesions, and improve vascular 
reactivity in animal models and in humans [32]. Apo AI 
in HDL  [35]  and plasma glutathione peroxidase [36] 
reduce PC hydroperoxides, and an infusion of apo AI-
PC discs raising low HDL is effective in restoring the 
endothelial function [37].  
EFFECTS OF GENE-ACTIVATING 
COMPOUNDS ON LIVER ER, RISK FACTORS, 
ATHERO-SCLEROSIS AND SURVIVAL 
Healthy young nonobese subjects show high 
plasma HDL-C and HDL2–C and high HDL-C/ total 
cholesterol (T-C) and HDL2-C/HDL3-C ratio together 
with high plasma antipyrine (AP) clearance rate [38], 
which has been used as a measure of hepatic P450-
activity  in vivo.  Functional crosstalk of  common 
regulatory factors links lipid and xenobiotic metabolism 
and P450 activity [31, 39, 40]. A prospective, double-
blind, placebo-controlled trial including nonepileptic 
subjects showed that phenytoin therapy raises plasma 
HDL-C, and particularly HDL2-C, and has no significant 
effect on HDL3-C, LDL-C, T-C and triglycerides [41].  
Plasma HDL-C and apo A-I raise with increasing 
protein, PL (Fig. 1) [17], and P450 in the liver, and they 
are high in subjects undergoing gene-activating drug 
therapy [6, 42]. The subjects also show low LDL-C and 
LDL-C/HDL-C ratio [40] and high HDL2-C and HDL-C/ 
T-C ratio [38] together with high AP clearance rate. 
Plasma HDL-C, apo AI and HDL-C/ T-C ratio raise and 
triglycerides decrease with decreasing hepatic 
triglycerides [17], and fat content as determined 
microscopically  [43].  These  original studies linking 
gene activation, upregulation of hepatic ER functions, 
proteins, PL and P450 activity, with beneficial changes 
in key risk factors presented novel mecahanisms to 
prevent and treat atherosclerotic vascular disease [5, 
31]. 
Hepatic CTP:phosphocholine cytidylyltransferase- 
(CCT), the regulatory enzyme for the synthesis of PC, 
is a key player in maintaining plasma HDL-C level [44]. 
Elevation of cellular cholesterol induces generation of 
oxysterols that upregulate CCT and PC synthesis 
[45]. PC is the most important PL in reverse cholesterol 
transport because it is the essential cholesterol-binding 
component of lipoproteins and the acyl donor in the Gene-Activation Mechanisms Against Diseases  Current Molecular Medicine,  2011, Vol. 11, No. 5     393 
esterification of free cholesterol by lecithin:cholesterol 
acyltransferase (LCAT) [26]. In agreement with these 
studies, high PL content in HDL2 particles has been 
found to be an efficient driving factor for cholesterol 
removal from peripheral cells [46, 47], an intravenous 
infusion of apo AI/PC discs to stimulate reverse 
cholesterol transport in humans [48], and plasma HDL-
PL levels to inversely correlate to the extent of 
atherosclerosis in coronary arteries [49].  
Numerous xenobiotic compounds upregulate 
antiatherogenic mechanisms (reviewed in [50]). The 
compounds include drugs for dyslipidemias such as 
statins, niacin, fibrates, resins, as well as compounds 
for other purposes, including angiotensin converting 
enzyme (ACE) inhibitors, angiotensin receptor 
blockers, calcium channel blockers, glitazones and 
anticonvulsants, and alcohol. A number of xenobiotic 
gene-activators raise HDL2-C [50] and produce plasma 
lipoprotein pattern which is typical of low risk of 
atherosclerotic disease and exceptional longevity [51, 
52], regress atherosclerosis, and reduce mortality and 
/or morbidity from CHD, cerebrovascular disease, and 
also death from any cause [50].  
EFFECTS OF GENE-ACTIVATORS ON LIVER 
ER AND GLUCOSE AND INSULIN  
Clinical investigations performed in the 1980s 
evaluated the effects of gene-activating agents on 
glucose and insulin. The studies including DM2 
patients revealed that the therapy induces plasma 
membrane reparation and increases the surface 
density in ER membranes of hepatocytes together with 
an elimination of liver fat,  a decrease both in blood 
glucose and plasma  IRI  levels and enhancement of 
P450-mediated AP clearance [7].  These original 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Relation of liver phospholipid and protein concentrations to plasma HDL cholesterol (r=0.878 and r=0.670, 
respectively), apolipoprotein A-I (r=0.812 and r=0.614) and A-II (r=0.433 and r=0.408) levels in 23 subjects. Reproduced from: 
Luoma PV, et al. Acta Med Scand., 1983; 214: 103-109 [17].  








      
	

		





























	







	







	






	




	







	







	
	






	
	

	
394    Current Molecular Medicine,  2011, Vol. 11, No. 5  P.V. Luoma 
observations linking upregulation of ER membranes 
and functions and lowering of glucose and IRI levels 
presented a novel approach  for the prevention and 
treatment of DM2 [7]. Subsequent studies clarified, by 
using the euglycemic clamp technique,  the effects of 
gene-activating compounds on  glucose-  insulin 
homeostasis  both in healthy volunteers and patients 
with DM2 [8, 53]. The results revealed that a short-term 
PB treatment of healthy volunteers increases glucose 
disposal rate by approximately 30% and also the 
metabolic clearance rate of glucose, with concomitant 
enhancement of AP elimination [53]. PB therapy also 
reduced fasting IRI, while fasting blood glucose in 
healthy subjects remained unaltered. In contrast to PB 
effects, cimetidine, an inhibitor of P450, reduced 
glucose disposal rate and glucose metabolic clearance 
rate, and AP elimination [53].  
In subjects with liver disease glucose disposal rate 
varies proportionately to the amount of unaltered 
hepatic parenchyma as evaluated morphometrically, 
and to hepatic P450-mediated AP kinetics [54]. The 
glucose disposal rate was lowest among patients with 
fatty liver and those with liver cirrhosis. PB treatment of 
DM2 patients reduced both fasting blood glucose and 
IRI [8].  In addition, glucose disposal  rate, metabolic 
clearance rate of glucose, and insulin sensitivity index, 
determined by using the euglycemic clamp technique, 
increased during therapy (Fig. 2) [8].  
Glucose has recently been identified as a natural 
LXR agonist [21].  It activates LXR at physiological 
concentrations expected in the liver and induces 
expression of LXR target genes with efficacy similar to 
that of oxysterol and determines its own fate [21]. 
Glucose binds and stimulates the transcriptional activity 
of LXR and coordinates hepatic lipid metabolism. 
Hepatic LXR activation  suppresses gluconeogenic 
genes, and induces glucokinase in the liver that 
promotes hepatic glucose utilization [55].  
COGNITIVE IMPAIRMENT – MECHANISMS 
AND RISK FACTORS 
Mild Cognitive Impairment (MCI) has been used to 
describe the transitional state between normal 
cognitive function and Alzheimer`s disease (AD). AD is 
the most common cause of dementia [56], the 
prevalence of which doubles every five years between 
65 and 85 years of age [57]. The accumulation of 
amyloid  (A) in the brain has been considered as the 
main culprit  in the pathogenesis of AD, resulting in 
synapse disruption and neuronal destruction. Cognitive 
processes require gene expression modification to 
consolidate information, and transcriptional 
dysregulation could perturb neuronal function and 
cognitive performance [58]. 
Recent studies in the AD context have focused 
attention on LXRs [9, 59] and the so-called LXR-
ABCA1- apo E axis [10, 60]. LXRs have an important 
function in lipid homeostasis in the brain, and the loss 
of the receptors leads to neuroregenerative processes 
[59]. ABCA1 has been shown to influence brain levels 
and lipidation of apo E in mice. A poor lipidation of apo 
E increases amyloid burden in mouse models of AD 
and, conversely, an overexpression of ABCA1 in the 
brain promotes apo E lipidation and reduces the 
formation of mature amyloid plaques [60].  LXR 
activating compounds reducing amyloid load also 
improve cognitive performance in mouse models of AD 
[61]. An activation of pregnane X receptor (PXR) may 
also improve cognitive function. Pregnenolone-16-
carbonitrile (PCN), a PXR agonist, has been shown to 
induce the expression of blood-brain barrier protein 
known as P-glycoprotein, and to reduce brain A levels 
in a mouse model of AD [62]. This protein specifically 
mediates the efflux transport of A from mouse brain 
capillaries into vascular space, a critical component of 
the A brain efflux mechanism [69]. A recent study 
using a mouse model of AD and analyzing the effects 
of phenylbutyrate, revealed that the drug reduces AD 
linked tau protein and ameliorates cognitive deficit [58]. 
The drug is already approved for clinical use, and it 
may provide a novel approach for the treatment of AD 
[58].  
Low HDL has been identified as a risk factor for 
deficit and decline in memory in midlife [63], and high 
HDL-C and apo AI concentrations correlate with 
cognitive function in advanced age [64]. 
Hyperinsulinemia associated with insulin resistance 
reduces insulin transport across the blood brain barrier, 
BBB, and subsequently lowers insulin levels and 
activity in the brain. The reduced brain insulin signaling 
associates with increased A levels in mouse model of 
diabetes [65], and hyperinsulinemia increases risk of 
AD in man [56]. CYP enzymes could also influence the 
development of AD [66]. Polymorphism of CYP46, the 
cholesterol metabolizing enzyme in the brain, has been 
shown to influence brain A- load, cerebrospinal fluid 
levels of A peptides, and the risk of late-onset AD in 
man [67].  
DISTURBANCE AND RESTORATION OF ER 
FUNCTION AND METABOLIC DISEASE  
Recent studies on the pathogenesis of metabolic 
diseases have clarified mechanisms that by disturbing 
ER homeostasis cause accumulation of unfolded or 
misfolded proteins and result in a state known as ER 
stress [68, 69]. During ER stress, these proteins are 
prevented from trafficking to their proper subcellular 
localizations and are usually rapidly regraded [70]. A 
disruption in the condition of this organelle affects the 
fate of lipids, proteins, glucose and insulin and 
associates with common ailments including 
atherosclerosis, DM, obesity  and neurodegenerative 
disease [31,  70]. ER responds to the stress by 
triggering signalling cascade called unfolded protein 
response (UPR) for restoring the metabolic balance. A 
failure in this response can promote the  disease 
process. The UPR maintains ER homeostasis by two 
connected mechanisms; by providing new ER-folding 
machinery and by providing ER expansion with Gene-Activation Mechanisms Against Diseases  Current Molecular Medicine,  2011, Vol. 11, No. 5     395 
increase in ER surface area and luminal space [71]. 
Gene-activating agents including P450-inducers 
increase ER size through membrane synthesis [31] that 
is an integral yet distinct part of the cellular program to 
overcome ER stress [71]. Chaperones are specialized 
proteins with a key role in cellular homeostasis by 
assisting in protein folding, assembly of the 
macromolecular complexes, protein transport and 
cellular signalling [70].  
A dysregulation of  ER function causing fatty 
regeneration in the liver, unfavorably affects lipoprotein 
metabolism, while an activation of ER functions 
increases ER membranes, reduces hepatic lipid 
deposition [7, 18],  and has beneficial effects on 
lipoprotein risk factors [6].  X box-binding protein 1 
(XBP-1) is a transcription factor which directs cells to 
construct more ER membranes for  maintaining ER 
function [72]. An activation of the factor enhances 
CCT activity and the synthesis of protein and PC, 
which is the principal PL of ER membranes and plasma 
lipoproteins  [44].  Gene-activating compounds induce 
protein and PC synthesis and increase PC-rich HDL2 
[50].  The PCs are essential cholesterophilic 
components of HDL2 in the reverse transport and 
elimination of cholesterol [26].  
An accumulation of cholesterol and other lipids in 
macrophages can cause ER stress and eventually lead 
to the death of the cells [68]. Macrophage death in 
advanced atherosclerotic lesions could have 
deleterious consequences, such as exacerbated 
metabolic dysreglation and the rupture of vascular 
plaques. Phenylbutyrate, a chemical chaperone has 
been shown to mitigate macrophage ER stress and 
apoptosis in atherosclerotic lesions in vivo, indicating 
that the therapy improving ER chaperoning function 
can protect against the deleterious effects of toxic lipids 
in promoting atherosclerotic lesions [73].  
Factors disturbing ER function  affect the fate of 
glucose and promote hyperglycemia through insulin 
resistance, stimulation of hepatic glucose production 
and suppression of glucose disposal [8, 68], and gene-
activating therapy can restore normal glucose-insulin 
homeostasis [7, 8]. Lipid, protein and glucose 
metabolism are linked and, correspondingly, DM2 
patients show improvement of both glucose tolerance 
and plasma lipoprotein profile together with increase in 
liver PL and P450 [19]. An analysis of biopsies from 
obese subjects after weight loss and subsequently 
reduced adiposity after gastric bypass surgery showed 
reduced ER stress in liver and adipose tissue together 
with a 90 % decrease in liver triglyceride content and 
improvement of insulin sensitivity [74]. 
Tauroursodeoxycholic acid (TUDCA),  a chemical 
chaperone used to treat cholelithiasis and cholestatic 
liver disease, has been shown to alleviate ER stress in 
obese and diabetic mouse models, normalize 
hyperglycemia, increase insulin sensitivity, resolve the 
fatty liver disease and enhance insulin action in liver, 
muscle and adipose tissues [75]. First studies testing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Change in glucose disposal rate (A), in metabolic clearance rate of glucose (B) and insulin sensitivity index (C) for 
individual type 2 diabetic subjects during glucose clamp studies performed using an insulin infusion rate of 1 mU/ kg before and 
after Phenobarbital therapy. Reproduced from: Lahtela JT, et al. Diabetes, 1985; 34: 911-6 [8], with permission from American 
Diabetes Association.  
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TUDCA in obese subjects with insulin resistance have 
also resulted in promising results, an increase in 
hepatic and muscle insulin sensitivity [76].  
METABOLIC AND HEALTH EFFECTS OF 
LIFESTYLE FACTORS  
Major lifestyle factors affecting health include poor 
dietary habits together with unhealthy composition of 
the diet with excess calories, physical inactivity, 
inadequate weight control, obesity, smoking, and 
excessive alcohol consumption.  
Dietary factors  have favorable metabolic effects. 
Weight control by a low calorie diet with adequate 
nutrition increases insulin sensitivity and reduces 
insulin secretion [77]. The effect of the diet on sirtuin 1 
(SIRT1) could contribute to atheroprotection. The 
enzyme is an activator of LXR and cholesterol efflux via 
HDL formation. SIRT1 overepression could also induce 
hepatic CYP7A1, decrease hepatic cholesterol and via 
upregulation of the LDLR pathway reduce plasma LDL-
C [78, 79]. Diet constituents such as soy proteins and 
alcohol upregulate apo AI gene and raise HDL-C [80], 
and vitamin B3 or niacin increases apo AI production 
[81].  Natural mechanisms modify the effects of 
unhealthy diet.  A278C polymorphism in hepatic 
CYP7A1 gene affects the effect of a high-cholesterol 
diet on plasma  HDL-C and  cholesterol [82].  The 
increase in plasma cholesterol in the subjects with CC 
(Cytosine – Cytosine) genotype was mainly due to the 
larger increase in HDL-C.  The activation of nuclear 
receptors could also modify the effect of the diet. 
Recent studies revealed that activation of constitutive 
androstane receptor (CAR) which is highly expressed 
in the liver, prevents diet-induced obesity, reduces 
hepatic steatosis, improves insulin sensitivity [83], and 
ameliorates diabetes and fatty liver disease in mice 
[84].  
Dietary factors activating ER functions and 
stimulating cholesterol effluxing mechanisms, prevent 
and regress atherosclerosis. Moderate alcohol 
consumption protects from both atherosclerotic disease 
and dementia  [85], and reduces CHD and all-cause 
mortality [31], and the Mediterranian-type of diet has 
multiple beneficial effects. The people on the diet have 
low blood pressure and fasting blood glucose and IRI 
levels, an antiatherogenic plasma risk factor profile 
[86],  and low mortality rate from CHD, CVD, cancer, 
and also total mortality [50]. Adherence to the diet also 
associates with reduced risk of AD [87]. A healthy diet 
also reduces insulin secretion and increases insulin 
sensitivity and  prevents the occurrence of metabolic 
syndrome [88], and also DM2 in people with impaired 
glucose tolerance [89], both of which impair cognitive 
performance [56]. 
Regular physical activity has beneficial metabolic 
effects (reviewed in [50]). It upregulates receptors such 
as LXR, PPAR (peroxisome proliferator-activated 
receptor ), scavenger receptor B1 (SRB1) and LDLR, 
enzymes  such as CYPs, LCAT and paraoxonase 1, 
and transporters such as ABCA1, ABCG1 and apo AI. 
It also raises plasma apo AI, HDL-C and HDL2-C, and 
decreases LDL-C, cholesterol and triglycerides, and 
promotes cellular cholesterol efflux. Regular exercise 
improves oxygen uptake and weight control, lowers 
blood pressure, upregulates  mechanisms protecting 
arteries from atherosclerosis and also decreases CHD, 
cardiovascular, cancer, and also total mortality [50]. 
Moderate exercise performed in midlife or late life also 
associates with later reduced odds of having MCI [90], 
and reduces the risk for AD [87]. In addition, physical 
activity reduces insulin resistance and postprandial 
hyperglycemia, improves glucose tolerance and 
prevents the development of DM2 in cases with 
impaired glucose tolerance [89].  
DISCUSSION  
Both endogenous and exogenous factors including 
living habits activate functions of genes with favorable 
effects on major health problems. The gene-activators 
regress atherosclerosis, by normalization blood 
glucose – insulin homeostasis remove metabolic 
syndrome and DM2, and prevent cognitive decline and 
dementia. Morover, preclinical animal studies show that 
the compounds eliminate amyloid from brain plaques 
and improve cognitive performance.  The compounds 
induce reparation and expansion  of ER membranes 
and normalize or improve  ER functions that maintain 
cellular metabolic homeostasis. They protect cells from 
the effects of inflammation and immune response and 
eliminate fat in cases with hepatic fatty degeneration. 
The gene-activation mechanisms correcting disturbed 
ER functions eliminate ER stress that links 
atherosclerosis, obesity, insulin action and DM2.  
Together with inducing protein synthesis and 
reparation of cellular structures, the gene-activators 
increase hepatic protein and PL and stimulate enzymes 
including CYPs and glucokinase. They also upregulate 
NRs, apolipoproteins and ABC transporters, and further 
produce antiatherogenic plasma lipoprotein profile and 
enhance glucose disposal rate and insulin sensitivity. 
Numerous gene-activators raise plasma HDL2 with 
high PC content [50],  effective driving factor in key 
steps of the reverse cholesterol transport [26],  and 
DM2 patients show improved glucose tolerance with 
increase in liver PL and P450 [19].  
The liver has a key role  in glycemic control. It 
produces more than 90% of endogenous glucose, and 
as much as 40% of alimentary glucose is taken up by 
the liver,  and alterations in hepatic function influence 
glucose flux [91].  Gene-activating drug therapy 
reducing blood glucose induces hepatic glucokinase 
[23] which has been considered as a potential key 
target for glucose lowering therapy. A recent study 
showing that restoration of hepatic glucokinase 
expression beneficially corrects hepatic glucose flux 
and normalizes plasma glucose in diabetic fatty rats, 
supports this possibility [91].  Gene-Activation Mechanisms Against Diseases  Current Molecular Medicine,  2011, Vol. 11, No. 5     397 
The NRs are ligand-activated transcription factors 
that control a wide variety of metabolic processes by 
regulating the expression of genes encoding enzymes, 
transporters and other proteins involved in metabolic 
homeostasis [92]. NRs  with known physiological 
ligands include endocrine receptors and adopted and 
enigmatic orphan receptors [92]. Ligands for endocrine 
NRs include glucocorticoid, mineralocorticoid, 
androgen, estrogen, thyroid hormone, retinoid acid and 
vitamin D. Table 1 presents ligands for orphan NRs 
with favorable metabolic effects.  
Large population studies indicate that absence in 
middle age of modifiable risk factors such as 
overweight, hyperglycemia, dyslipidemia and 
hypertension, are positively related to exceptional 
survival in old age [98, 99]. The reviewed studies 
indicate that these risk factors typical of metabolic 
syndrome are linked with the disturbed hepatic ER 
function affecting the fate of lipids, proteins, glucose 
and insulin.The studies also show that gene-activating 
therapy can eliminate abnormalities in the syndrome. It 
eliminates liver fat and reduces elevated plasma 
triglycerides and raises low HDL-C. The therapy can 
also normalize glucose tolerance and insulin level, 
promote weight control and reduce blood pressure. 
Healthy lifestyle choices together with natural gene 
activation have an important role in normalization of 
metabolic abnormalities, weight control and elimination 
of obesity, and decreasing blood pressure.  
HDL has anti-inflammatory, antioxidant, antiapop-
topic, neuroprotective, vasodilatory and anti-thrombotic 
effects that protect cells from the effects of aging 
process  [51]. Plasma HDL levels decline with age in 
prospective studies but cross-sectionally, by contrast, 
they do not change much or even slightly increase with 
age suggesting that people with still high HDL levels 
survive [51, 52]. In very old people age correlates 
positively with HDL2, a low HDL is very rare among 
them [51], and high HDL-C and apo AI correlate with 
cognitive function in advanced age [64].  
A number of factors  and activities can prevent 
cognitive impairment in man. Elimination of modifiable 
reasons of obesity, DM, dyslipidemia, heart disease, 
stroke, and hypertension, delays cognitive decline and 
development of dementia [11, 100]. Active participation 
in stimulating cognitive, social, and physical activities, 
and healthy diet, also have a positive delaying effect on 
the onset of dementia [11, 100]. Studies showing that 
carotid intimal thickness predicts accelerated cognitive 
decline among adults without clinical vascular disease 
[101], and that atherosclerosis in intracerebral arteries 
is an independent risk factor for dementia [102], 
indicate that activities and therapies protecting arteries 
from atherosclerosis are central  for maintaining 
cognitive health.  
Table 1.  Orphan NRs and their Ligands with Effects on Metabolic Disorders/Diseases 
 
Receptor  Endogenous ligand  Exogenous ligand   Disorder/Disease  References 
LXR  Oxysterols, bile acids  TO901317  Dyslipidemia, 
atherosclerosis 
[27, 92, 93] 
LXR Glucose  GW3965  Hyperglycemia  [21,  94] 
PPAR Fatty  acids  Fibrate  Dyslipidemia, 
atherosclerosis 
[92] 
PPAR Fatty  acids  Glitazone  DM, glucose intolerance, 
insulin resistance 
[92] 
PPAR  –    Statin  Dyslipidemia, 
atherosclerosis 
[95] 
PPAR  Fatty acids  GW501516  Dyslipidemia, 
atherosclerosis 
[92] 
PXR  Bile acids  Rifampicin  Cholestasis, jaundice  [92, 96] 
PXR-CAR   Phenobarbital  DM2, glucose intolerance, 
insulin resistance 
[7, 8] 
PXR-CAR   Phenobarbital  Hepatic  steatosis  [7,  20] 
PXR-CAR   Phenobarbital  Hyperbilirubinemia, 
cholestasis 
[93] 
CAR  Steroids, Bile acids  CITCO  Cholestasis, jaundice  [92, 93] 
CAR   TCPOBOP  Glucose intolerance, 
insulin resistance, fatty 
liver 
[83, 84] 
FXR  Bile acids  Chenodeoxycholic acid  Cholestasis  [92] 
FXR   GW4046  Dyslipidemia, 
hyperglycemia, insulin 
resistance 
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CONCLUSIONS  
Both endogenous and exogenous factors including 
living habits influence life maintaining functions. They 
activate genes in the processes that beneficially affect 
the fate of lipids, proteins and glucose,  and protect 
cells from the effects of aging process. Gene-activating 
compounds induce reparation of altered cellular 
structures consequent to ER stress, and normalize and 
improve metabolic functions. They prevent and regress 
atherosclerosis and, by restoring normal glucose-
insulin homeostasis, remove metabolic syndrome and 
DM2. The gene-activation produces positive changes 
that  eliminate major cardiovascular and metabolic 
diseases, prevent cognitive impairment and dementia, 
and promote well-being and active living in advanced 
age.  
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ABBREVIATIONS 
ABC =  ATP-binding  cassette 
AD =  Alzheimer`s  disease 
AP =  antipyrine 
apo =  apolipoprotein 
CAR  =  constitutive androstane receptor 
CCT =  CTP:phosphocholine 
cytidylyltransferase- 
CHD  =  coronary heart disease 
CYP =  cytochrome 
ER =  endoplasmic  reticulum 
FXR =  farnesoid  X  receptor 
HMGCoAR =  hydroxymethylglutaryl-coenzyme  A 
reductase 
IRI =  immunoreactive  insulin 
LCAT =  lecithin:cholesterol  acyltransferase 
LDLR  =  low density lipoprotein receptor 
LXR =  liver  X  receptor 
PB =  phenobarbital 
PC =  phosphatidylcholine 
PPAR =  peroxisome  proliferator-activated 
receptor 
PXR  =  pregnane X receptor 
SIRT1 =  sirtuin  1 
T-C =  total  cholesterol 
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